{"transactions":[{"id":1989977,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":6073949,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"shares","element":"transactionShares","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting and dispositive power over the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting and dispositive power over the shares held by SVP X. Dr. Healy and Dr. Katabi are the managing member of SM X LLC and may be deemed to have shared voting and dispositive power over the shares held by SVP X. Each of Dr. Healy and Dr. Katabi disclaims beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":1989976,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2023-02-24","kind":"disposition_to_issuer","acquired":false,"shares":19608,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This line item represents Shares of common stock held by the Dr. Healy that were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Issuer. At the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each Share issued upon early exercise of an option that is subject to vesting, repurchase or other lapse restrictions was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This line item represents Shares of common stock held by the Dr. Healy that were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Issuer. At the effective time of the Merger, pursuant to the Merger Agreement, except as otherwise set forth in the Merger Agreement, each Share issued upon early exercise of an option that is subject to vesting, repurchase or other lapse restrictions was accelerated and became fully vested and was cancelled and automatically converted into the right to receive, without interest, the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":1989975,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2023-02-24","kind":"other","acquired":false,"shares":9803,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"shares","element":"transactionShares","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the \"Issuer\"), AstraZeneca Finance and Holdings Inc. (\"Parent\") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (i) $26.00 per Share in cash (the \"Cash Amount\"), plus (ii) one contingent value right (each, a \"CVR\") per Share representing the right to receive a contingent payment of $10.00 per share, [continues to footnote (4)]"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"[continues from footnote (3)] in cash, upon the achievement of a specified milestone by December 31, 2033 (the Cash Amount plus one CVR, collectively, the \"Offer Price\"), in each case, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price."}],"balance_after":19608,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":1989974,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":2,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":3,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":4,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":5,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-27T21:15:49.000Z","date":"2022-11-28","kind":"sale","acquired":false,"shares":6000,"price":14.32,"value":85920.0,"ownership":{"direct":false,"nature":"By Sofinnova Synergy Master Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.30 to $14.35 inclusive. Dr. Healy undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Synergy Master Fund, LP (the \"Synergy Fund\"). Sofinnova Synergy Fund GP, LLC (the \"Synergy Fund GP\"), the general partner of the Syngery Fund, may be deemed to have sole voting and dispositive power over such shares. Dr. Healy is a managing member of the Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by the Synergy Fund. Dr. Healy disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-013481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919123013481/doc4.xml","form_type":"4"}},{"id":2026334,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116389,"kind":"organization","name":"Sofinnova Management X-A, L.L.C.","position":5,"cik":"0001965187","reported_name":"Sofinnova Management X-A, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-08T18:29:55.000Z","date":"2023-02-06","kind":"purchase","acquired":true,"shares":285714,"price":7,"value":1999998.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.P. (\"SM X LP\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. Sofinnova Management X-A, L.L.C. (\"SM X LLC\") is the general partner of SVP X LP and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3467156,"source":{"system":"sec-edgar","filing":"0001104659-23-014661","document":"tm235954-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465923014661/tm235954-1_4seq1.xml","form_type":"4"}},{"id":2185266,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T15:46:23.000Z","date":"2022-08-11","kind":"purchase","acquired":true,"shares":500000,"price":30,"value":15000000.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of such shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":6073949,"source":{"system":"sec-edgar","filing":"0001104659-22-091184","document":"tm2223413-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000110465922091184/tm2223413-2_4seq1.xml","form_type":"4"}},{"id":2397555,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2022-02-14T18:17:42.000Z","date":"2022-02-10","kind":"purchase","acquired":true,"shares":266666,"price":15,"value":3999990.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. Michael Powell, a Reporting Person on SVP X's prior Section 16 filings with respect to the Issuer, is no longer a managing member of SM X, and accordingly, is not a Reporting Person on this Form 4."}],"balance_after":3181442,"source":{"system":"sec-edgar","filing":"0001104659-22-023301","document":"tm226514d1_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000110465922023301/tm226514d1_form4.xml","form_type":"4"}},{"id":2435634,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-01-13T16:38:02.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":4275000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to  share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1257353},"source":{"system":"sec-edgar","filing":"0001209191-22-003197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000120919122003197/doc4.xml","form_type":"4"}},{"id":2435633,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2022-01-13T16:38:02.000Z","date":"2022-01-11","kind":"exercise","acquired":false,"shares":13571428,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to  share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3991596},"source":{"system":"sec-edgar","filing":"0001209191-22-003197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000120919122003197/doc4.xml","form_type":"4"}},{"id":2435632,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-13T16:38:02.000Z","date":"2022-01-11","kind":"purchase","acquired":true,"shares":325000,"price":16,"value":5200000.0,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to  share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":5573949,"source":{"system":"sec-edgar","filing":"0001209191-22-003197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000120919122003197/doc4.xml","form_type":"4"}},{"id":2435631,"issuer":{"id":116342,"kind":"organization","name":"CinCor Pharma, Inc.","symbol":"CINC"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-13T16:38:02.000Z","date":"2022-01-11","kind":"exercise","acquired":true,"shares":5248949,"ownership":{"direct":false,"nature":"By Sofinnova Venture Partners X, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration, on a 3.4:1 basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to  share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports."}],"balance_after":5248949,"source":{"system":"sec-edgar","filing":"0001209191-22-003197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680200/000120919122003197/doc4.xml","form_type":"4"}},{"id":2641487,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-07-06T20:28:23.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":10565238,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3401544},"source":{"system":"sec-edgar","filing":"0001104659-21-089440","document":"tm2121485-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921089440/tm2121485-4_4seq1.xml","form_type":"4"}},{"id":2641486,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:28:23.000Z","date":"2021-07-02","kind":"purchase","acquired":true,"shares":357142,"price":14,"value":4999988.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3758686,"source":{"system":"sec-edgar","filing":"0001104659-21-089440","document":"tm2121485-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921089440/tm2121485-4_4seq1.xml","form_type":"4"}},{"id":2641485,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-06T20:28:23.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":3401544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.1060103 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy and Maha Katabi are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":3401544,"source":{"system":"sec-edgar","filing":"0001104659-21-089440","document":"tm2121485-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000110465921089440/tm2121485-4_4seq1.xml","form_type":"4"}},{"id":2707597,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-05-18T20:23:11.000Z","date":"2021-05-18","kind":"exercise","acquired":false,"shares":2187504,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":2187504},"source":{"system":"sec-edgar","filing":"0001209191-21-033818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919121033818/doc4.xml","form_type":"4"}},{"id":2707596,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-18T20:23:11.000Z","date":"2021-05-18","kind":"purchase","acquired":true,"shares":727272,"price":11,"value":7999992.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2914776,"source":{"system":"sec-edgar","filing":"0001209191-21-033818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919121033818/doc4.xml","form_type":"4"}},{"id":2707595,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-05-18T20:23:11.000Z","date":"2021-05-18","kind":"exercise","acquired":true,"shares":2187504,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2187504,"source":{"system":"sec-edgar","filing":"0001209191-21-033818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1245624/000120919121033818/doc4.xml","form_type":"4"}},{"id":2871905,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1200228,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1200228},"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871904,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1104209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1104209},"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871903,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":450000,"price":20,"value":9000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2754437,"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871902,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1200228,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2304437,"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":2871901,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":3,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":4,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-09T23:04:01.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":1104209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the \"IPO\") and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1104209,"source":{"system":"sec-edgar","filing":"0001104659-21-016806","document":"tm215893d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000110465921016806/tm215893d1_4.xml","form_type":"4"}},{"id":3074862,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2020-07-28T18:08:19.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":11888112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1590808},"source":{"system":"sec-edgar","filing":"0000899243-20-020562","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020562/doc4.xml","form_type":"4"}},{"id":3074861,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T18:08:19.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":437500,"price":16,"value":7000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":2028308,"source":{"system":"sec-edgar","filing":"0000899243-20-020562","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020562/doc4.xml","form_type":"4"}},{"id":3074860,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T18:08:19.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":1590808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1590808,"source":{"system":"sec-edgar","filing":"0000899243-20-020562","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020562/doc4.xml","form_type":"4"}},{"id":3095397,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":12643557,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":599988},"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095396,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":18044028,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":856262},"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095395,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":58823,"price":17,"value":999991.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1515073,"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095394,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":599988,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":1456250,"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}},{"id":3095393,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":116390,"kind":"organization","name":"Sofinnova Venture Partners X, L.P.","position":1,"cik":"0001680200","reported_name":"Sofinnova Venture Partners X, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":116388,"kind":"organization","name":"Sofinnova Management X, L.P.","position":2,"cik":"0001680194","reported_name":"Sofinnova Management X, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38748,"kind":"person","name":"HEALY JAMES","position":3,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79666,"kind":"person","name":"Katabi Maha","position":4,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39729,"kind":"person","name":"POWELL MICHAEL","position":5,"cik":"0001202793","reported_name":"POWELL MICHAEL","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T21:36:15.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":856262,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Sofinnova Venture Partners X, L.P. (\"SVP X\"). Sofinnova Management X, L.L.C. (\"SM X\") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein."}],"balance_after":856262,"source":{"system":"sec-edgar","filing":"0001104659-20-080030","document":"tm2023913-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465920080030/tm2023913-1_4.xml","form_type":"4"}}]}